Alkermes Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Alkermes stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALKS, but not buy additional shares or sell existing shares.
View analyst ratings for Alkermes or view top-rated stocks.

Wall Street analysts have given Alkermes a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Alkermes wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Alkermes is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Alkermes.

Alkermes plc (NASDAQ:ALKS) released its quarterly earnings results on Tuesday, July, 27th. The company reported $0.30 EPS for the quarter, topping the Zacks' consensus estimate of $0.12 by $0.18. The business had revenue of $303.72 million for the quarter, compared to analysts' expectations of $277.83 million. Alkermes had a positive trailing twelve-month return on equity of 3.21% and a negative net margin of 5.71%.
View Alkermes' earnings history.

Alkermes' stock was trading at $16.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ALKS shares have increased by 85.3% and is now trading at $30.11.
View which stocks have been most impacted by COVID-19.

Alkermes issued an update on its FY 2021 earnings guidance on Wednesday, August, 4th. The company provided earnings per share (EPS) guidance of $0.520-$0.700 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.510. The company issued revenue guidance of $1.15 billion-$1.19 billion, compared to the consensus revenue estimate of $1.14 billion.

5 analysts have issued twelve-month price objectives for Alkermes' shares. Their forecasts range from $25.00 to $36.00. On average, they anticipate Alkermes' stock price to reach $28.25 in the next year. This suggests that the stock has a possible downside of 6.2%.
View analysts' price targets for Alkermes or view top-rated stocks among Wall Street analysts.

119 employees have rated Alkermes CEO Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among Alkermes' employees.

Some companies that are related to Alkermes include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Novavax (NVAX), Repligen (RGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of ALKS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), (CELG), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Alkermes' stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (14.16%), Vanguard Group Inc. (10.29%), BlackRock Inc. (8.08%), Sarissa Capital Management LP (7.36%), Primecap Management Co. CA (4.07%) and Renaissance Technologies LLC (3.27%). Company insiders that own Alkermes stock include Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops and Wendy L Dixon.
View institutional ownership trends for Alkermes.

ALKS stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Point72 Asset Management L.P., Credit Suisse AG, Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, UBS Asset Management Americas Inc., Russell Investments Group Ltd., and Man Group plc. Company insiders that have sold Alkermes company stock in the last year include Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Iain Michael Brown, Michael J Landine, Richard F Pops, and Wendy L Dixon.
View insider buying and selling activity for Alkermes or view top insider-selling stocks.

ALKS stock was purchased by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, BlackRock Inc., Northern Trust Corp, Goldman Sachs Group Inc., Geode Capital Management LLC, Canada Pension Plan Investment Board, Vanguard Group Inc., and Bank of New York Mellon Corp. Company insiders that have bought Alkermes stock in the last two years include Emily Peterson Alva, and Nancy Wysenski.
View insider buying and selling activity for Alkermes or or view top insider-buying stocks.

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALKS stock can currently be purchased for approximately $30.11.

Alkermes has a market capitalization of $4.86 billion and generates $1.04 billion in revenue each year. The company earns $-110,860,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.

Alkermes employs 2,245 workers across the globe.

The following companies are subsidiares of Alkermes: Rodin Therapeutics.

Alkermes was founded in 1987.

The official website for Alkermes is www.alkermes.com.

Alkermes is headquartered at 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4.

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at (531) 772-8000 or via email at [email protected].